CXCL10 AS PREDICTIVE BIOMARKER OF RENAL TRANSPLANT ACUTE REJECTION AND DIAGNOSTIC BIOMARKER OF ANTIBODY-MEDIATED REJECTION (ABMR)

摘要

The invention relates to a method for determining whether a renal transplanted patient is at risk of acute rejection, comprising a step of determining the expression level of the CXCL10 polypeptide in a urine sample obtained from said patient until 3 -months post-transplantation. The invention also relates to a method for diagnosing antibody-mediated rejection (ABMR) in a renal transplanted patient, comprising a step of determining the expression level of the CXCL10 polypeptide in a urine sample obtained from said patient.